快速开发生产工艺，以实现未来百万剂量规模腺病毒载体 COVID19 疫苗的生产-猫眼课题宝

快速开发生产工艺，以实现未来百万剂量规模腺病毒载体 COVID19 疫苗的生产

批准号：

MC_PC_19058

负责人：

Alexander Douglas

金额：

$52.42万

依托单位：

University of Oxford

依托单位国家：

英国

项目类别：

Intramural

财政年份：

2020

资助国家：

英国

项目状态：

已结题

起止时间：

2020 至 --

来源：

https://gtr.ukri.org/projects?ref=MC_PC_19058

关键词：

Rapid development manufacturing processes future

项目摘要

项目成果

Alexander Douglas的其他基金

相似基金

相关文献

中文摘要

翻译

几种COVID-19候选疫苗正在开发中。UOXF开发的“ChAdOx 1 nCoV”是一个领先的候选者。在临床试验中，基于相同腺病毒技术的其他疫苗已被证明是安全的，并诱导强烈的免疫反应。在猴子身上，一种针对MERS病毒（与COVID-19非常相似）的疫苗只需一剂就能实现保护。我们将很快进行ChAdOx 1 nCoV的临床试验，但我们需要准备尽快生产数百万剂ChAdOx 1 nCoV，同时进行临床试验。该项目旨在尽快为高危人群提供超过100万剂的临床使用。

英文摘要

Several COVID-19 vaccine candidates are under development. ‘ChAdOx1 nCoV’, developed at UOXF, is a leading candidate. In clinical trials, other vaccines based upon the same adenovirus technology have proven to be safe and to induce strong immune responses. In monkeys, a vaccine against the MERS virus (which is very similar to COVID-19) achieved protection with a single dose. We will soon be performing clinical trials of ChAdOx1 nCoV, but we need to prepare to manufacture millions of doses of it as soon as possible, in parallel with the clinical trials. This project aims to enable availability of more than 1m doses for clinical use in high-risk groups as soon as possible.

期刊论文(8)

专著(0)

科研奖励(0)

会议论文

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

DOI： 10.1016/s0140-6736(20)32466-1

发表时间： 2021-12-19

期刊：

Lancet (London, England)

影响因子： --

作者：

[Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ, Oxford COVID Vaccine Trial Group]

通讯作者： Oxford COVID Vaccine Trial Group

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration.

DOI： 10.1038/s41541-023-00674-2

发表时间： 2023-06-05

期刊：

NPJ vaccines

影响因子： 9.2

作者：

[]

通讯作者：

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

DOI： 10.1016/s0140-6736(20)31604-4

发表时间： 2020-08-15

期刊：

LANCET

影响因子： 168.9

作者：

[Folegatti, Pedro M., Ewer, Katie J., Pollard, Andrew J.]

通讯作者： Pollard, Andrew J.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

DOI： 10.1016/s0140-6736(20)32661-1

发表时间： 2021-01-09

期刊：

Lancet (London, England)

影响因子： --

作者：

[Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group]

通讯作者： Oxford COVID Vaccine Trial Group

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

DOI： 10.1016/s0140-6736(21)00432-3

发表时间： 2021-03-06

期刊：

Lancet (London, England)

影响因子： --

作者：

[Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group]

通讯作者： Oxford COVID Vaccine Trial Group